Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368288 | 0.90 | SCN9A (0.44) | KIF11TRPV1LTA4H | |
| SCHEMBL20054187 | 0.81 | AKT1 (0.30) | — | |
| SCHEMBL6407483 | 0.81 | KDM1A (0.39) | MAOBKDM1ASCN2A | |
| SCHEMBL4403430 | 0.81 | KIF11 (0.44) | KIF11NISCHTRPV1NOTUM | |
| SCHEMBL311778 | 0.79 | IDO1 (0.54) | MAOBKDM1ASCN2ANOTUM | |
| SCHEMBL30641506 | 0.78 | NPSR1 (0.45) | KIF11MAOBKDM1A | |
| SCHEMBL464496 | 0.78 | MAPK1 (0.40) | MAOBGFERGSK3BALOX5 | |
| SCHEMBL9243197 | 0.77 | NISCH (0.44) | NISCHSCN2ANOTUMALOX5 | |
| SCHEMBL30641497 | 0.77 | TRPV4 (0.44) | — | |
| SCHEMBL443810 | 0.75 | MAPT (0.43) | GSK3BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| CN-101679439-A | P70S 6 kinase inhibitors | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1448554-A1 | PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003031437-A1 | PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | KIF11 3365/4885MAOB 2518/4885KDM1A 1014/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KIF11 2238/4885MAOB 4586/4885KDM1A 3854/4885 |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | KIF11 1955/4885MAOB 1313/4885KDM1A 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.